StockData
MBX Biosciences, Inc. logo

MBX Biosciences, Inc. (MBX) shareholders

MBXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$53.12−2.82 (-5.04%)

Close on Nov 16, 2026Market cap $2.56BP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
100.0%
55M of 48M shares
Institutional holders
173
39 new, 20 sold out
Net institutional buying
2M
In Q2 2026
Insider trades, 12 months
1 buys · 7 sales
Net sold $2.50M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Abigail P. Johnson
Joint filing with FMR LLC (15.00%)
7,224,00915.00%13G (passive) amendmentSep 30, 2026
Patrick J. Heron
Joint filing with Frazier Life Sciences X, L.P. (10.80%), Fhmls X, L.P. (10.80%) and 2 more
5,243,42111.70%13D (active) amendmentAug 6, 2026
Wellington Investment Advisors Holdings LLP
Joint filing with Wellington Management Group LLP (10.50%), Wellington Group Holdings LLP (10.50%) and 1 more
4,977,52310.50%13G (passive) amendmentJun 30, 2026
Edward T. Mathers
Joint filing with New Enterprise Associates 17, L.P. (8.10%), NEA Partners 17, L.P. (8.10%) and 9 more
3,619,4748.10%13D (active) amendmentNov 6, 2025
Orbimed Advisors LLC
Joint filing with Orbimed Capital Gp Vii LLC (5.20%)
3,074,8536.40%13D (active) amendmentAug 6, 2026
FMR LLC
Joint filing with Abigail P. Johnson (6.20%)
2,936,6846.20%13G (passive)Mar 31, 2026
Wellington Management Company LLP
Joint filing with Wellington Management Group LLP (7.90%), Wellington Group Holdings LLP (7.90%) and 1 more
2,638,5217.80%13G (passive) amendmentMar 31, 2025
BlackRock, Inc.2,628,1815.50%13G (passive)Jun 30, 2026
Paradigm BioCapital Advisors GP LLC
Joint filing with Paradigm BioCapital Advisors LP (5.20%), Senai Asefaw, M.D. (5.20%)
2,493,0155.20%13G (passive)Jun 16, 2026
Wellington Management Group LLP
Joint filing with Wellington Group Holdings LLP (6.80%), Wellington Investment Advisors Holdings LLP (6.80%) and 1 more
2,266,6286.80%13G (passive) amendmentJun 30, 2025

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of MBXValueChange% of portfolio
Frazier Life Sciences Management, L.P.6,652,01313.81%$367.19M–8.00%
FMR LLC5,322,88511.05%$293.82M+2,386,2010.01%
Wellington Management Group Llp4,977,52310.34%$274.76M+1,785,6990.05%
NEA Management Company, LLC3,614,4867.51%$199.52M–12.56%
Orbimed Advisors LLC3,428,7367.12%$189.27M−209,1513.51%
BlackRock, Inc.3,323,6726.90%$183.47M+382,2660.00%
Paradigm Biocapital Advisors LP2,508,0155.21%$138.44MNew2.59%
NVP Associates, LLC2,136,3354.44%$117.93M–35.93%
Deep Track Capital, LP1,732,5693.60%$95.64M−1,025,0001.39%
Polar Capital Holdings Plc1,608,5143.34%$88.79M−13,6720.21%
Vanguard Capital Management LLC1,477,3883.07%$81.55M−2040.00%
Aaron Wealth Advisors LLC1,167,7992.42%$64.46M−3773.27%
Driehaus Capital Management LLC1,056,5792.19%$58.32M+38,3670.34%
Kynam Capital Management, LP934,7991.94%$51.60M–2.85%
Woodline Partners LP900,0921.87%$49.69M+290.15%
Eventide Asset Management, LLC873,4921.81%$48.22M−16,5080.64%
State Street Corp864,4661.79%$47.72M+77,2580.00%
Price T Rowe Associates Inc /Md/814,8071.69%$44.98M−214,2000.00%
Parkman Healthcare Partners LLC800,1731.66%$44.17M+1364.52%
Geode Capital Management, LLC773,0721.61%$42.68M+102,6870.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 202617355M100.0%39 / 6449 / 2010M7M
Q1 202615753M100.0%39 / 4347 / 1812M6M
Q4 202513848M100.0%45 / 5325 / 257M7M
Q3 202511848M99.2%39 / 3029 / 915M4M
Q2 20258837M76.6%21 / 4014 / 125M4M
Q1 20257936M74.1%27 / 2415 / 104M1M
Q4 20246333M68.4%33 / 118 / 153M1M
Q3 20244530M62.9%45 / 00 / 030M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

185 funds held MBX in Q2 2026, 35% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of MBXValue% of fundAs of
Vanguard Total Stock Market Index Fund1,135,3752.36%$62.67M0.00%Jun 30, 2026
Eventide Healthcare & Life Sciences Fund873,4921.81%$48.22M2.70%Jun 30, 2026
Fidelity Advisor Biotechnology Fund817,6001.70%$53.90M2.45%Jul 31, 2026
iShares Russell 2000 ETF796,6291.65%$43.97M0.05%Jun 30, 2026
Fidelity Stock Selector Small Cap Fund636,1001.32%$41.94M0.57%Jul 31, 2026
Select Health Care Portfolio600,0001.25%$18.88M0.33%May 31, 2026
T. Rowe Price Health Sciences Fund, Inc.586,3091.22%$32.36M0.27%Jun 30, 2026
Fidelity Small Cap Growth Fund416,4200.86%$27.45M0.31%Jul 31, 2026
Fidelity Series Small Cap Opportunities Fund365,2000.76%$24.08M0.51%Jul 31, 2026
Fidelity Small Cap Index Fund339,4920.70%$22.38M0.07%Jul 31, 2026
BlackRock Health Sciences Opportunities Portfolio333,3500.69%$10.49M0.18%May 29, 2026
Fidelity Advisor Health Care Fund328,0000.68%$21.63M0.69%Jul 31, 2026
Fidelity Fund321,1000.67%$17.72M0.20%Jun 30, 2026
Vanguard Extended Market Index Fund305,9980.64%$16.89M0.02%Jun 30, 2026
VIP Contrafund Portfolio286,9000.60%$15.84M0.05%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Steven L. HoerterChairman, President and CEO, Director98,0450.20%Nov 12, 2026
P. Kent HawrylukPresident & CEO, Director1,214,4442.52%May 8, 2026
Salomon AzoulayChief Medical Officer14,0260.03%Nov 5, 2026
John W. SmitherChief Financial Officer28,0000.06%Aug 4, 2026
Richard BartramChief Financial Officer15,0000.03%Feb 3, 2026
Peter RadovichDirector––Oct 22, 2026
Patrick J. HeronDirector, 10% owner3,927,7748.16%Jun 5, 2026
Ora H. PescovitzDirector24,3290.05%Jun 5, 2026
Steven RyderDirector––Jun 5, 2026
Edward T. MathersDirector3,614,4867.51%Jun 5, 2026
Tiba AynechiDirector1,386,3352.88%Jun 5, 2026
Laurie StelzerDirector––Jun 5, 2026
James M. CorneliusDirector102,0820.21%Jun 6, 2025
Carl L. GordonDirector, 10% owner747,8871.55%Feb 19, 2025
Advisors Llc OrbimedDirector, 10% owner3,812,2157.92%Feb 19, 2025
Capital GP VII LLC OrbiMedDirector, 10% owner––Feb 19, 2025
Genesis GP LLC OrbiMedDirector, 10% owner3,255,0006.76%Feb 19, 2025
Fhmls X, L.L.C.10% owner––Sep 30, 2025
James N. Topper10% owner––Sep 30, 2025
Frazier Life Sciences X, L.P.10% owner––Sep 30, 2025
Fhmls X, L.P.10% owner9,772,21420.29%Sep 30, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Steven L. Hoerter
Chairman, President and CEO, Director
Nov 10, 2026Sale−4,893$54.82$268.23K78,045
Salomon Azoulay
Chief Medical Officer
Nov 4, 2026Sale−373$53.96$20.13K14,026
Salomon Azoulay
Chief Medical Officer
Aug 4, 2026Sale−370$65.77$24.33K14,399
John W. Smither
Chief Financial Officer
Aug 3, 2026Award+28,000––28,000
Steven L. Hoerter
President and CEO, Director
Aug 3, 2026Award+71,000––82,938
Salomon Azoulay
Chief Medical Officer
May 8, 2026Option exercise+55,000$10.46$575.30K69,769
Salomon Azoulay
Chief Medical Officer
May 8, 2026Sale(10b5-1 plan)−15,003$38.30$574.61K14,769
Salomon Azoulay
Chief Medical Officer
May 8, 2026Option exercise+15,003$16.00$240.05K29,772
Salomon Azoulay
Chief Medical Officer
May 8, 2026Sale(10b5-1 plan)−55,000$38.38$2.11M14,769
P. Kent Hawryluk
President & CEO, Director
May 6, 2026Sale−607$29.54$17.93K727,667
Salomon Azoulay
Chief Medical Officer
May 6, 2026Sale−231$29.54$6.82K14,769
Steven L. Hoerter
Director
May 1, 2026Award+11,938––11,938
P. Kent Hawryluk
President & CEO, Director
Mar 13, 2026Buy+18,500$28.41$525.59K486,777
P. Kent Hawryluk
President & CEO, Director
Feb 26, 2026Option exercise+28,768$16.00$460.29K728,274
Salomon Azoulay
Chief Medical Officer
Feb 2, 2026Award+15,000––15,000
P. Kent Hawryluk
President & CEO, Director
Feb 2, 2026Award+35,250––699,506
Richard Bartram
Chief Financial Officer
Feb 2, 2026Award+15,000––15,000
P. Kent Hawryluk
President & CEO, Director
Oct 24, 2025Option exercise+182,859$3.25$594.29K664,256
P. Kent Hawryluk
President & CEO, Director
Oct 20, 2025Buy+20,000$13.64$272.80K468,277
Steven L. Hoerter
Director
Oct 17, 2025Buy+20,000$13.25$265.00K20,000
Fhmls X, L.P.
10% owner
Sep 26, 2025Buy+666,666$18.00$12.00M5,219,440
Ora H. Pescovitz
Director
Apr 8, 2025Buy+7,693$5.89$45.31K24,329
Carl L. Gordon
Director, 10% owner
Feb 18, 2025Buy+94,100$10.84$1.02M747,887
Carl L. Gordon
Director, 10% owner
Feb 18, 2025Buy+49,070$10.84$531.92K3,255,000
Genesis GP LLC OrbiMed
Director, 10% owner
Feb 18, 2025Buy+49,070$10.84$531.92K3,255,000
Genesis GP LLC OrbiMed
Director, 10% owner
Feb 18, 2025Buy+94,100$10.84$1.02M747,887
Carl L. Gordon
Director, 10% owner
Feb 14, 2025Buy+17,962$9.90$177.82K3,176,390
Carl L. Gordon
Director, 10% owner
Feb 14, 2025Buy+29,540$9.85$290.97K3,205,930
Genesis GP LLC OrbiMed
Director, 10% owner
Feb 14, 2025Buy+29,540$9.85$290.97K3,205,930
Genesis GP LLC OrbiMed
Director, 10% owner
Feb 14, 2025Buy+17,962$9.90$177.82K3,176,390
P. Kent Hawryluk
President & CEO, Director
Feb 4, 2025Buy+50,000$10.69$534.50K448,277
Edward T. Mathers
Director, 10% owner
Sep 16, 2024Buy+500,000$16.00$8.00M3,614,486
Edward T. Mathers
Director, 10% owner
Sep 16, 2024Conversion+2,091,383––3,114,486
Edward T. Mathers
Director, 10% owner
Sep 16, 2024Conversion+1,023,103––1,023,103
Tiba Aynechi
Director
Sep 16, 2024Conversion+1,386,335––1,386,335
Tiba Aynechi
Director
Sep 16, 2024Buy+750,000$16.00$12.00M2,136,335
James M. Cornelius
Director
Sep 16, 2024Conversion+102,082––102,082
Fhmls X, L.P.
10% owner
Sep 16, 2024Buy+625,000$16.00$10.00M4,552,774
Fhmls X, L.P.
10% owner
Sep 16, 2024Conversion+3,927,774––3,927,774
Forest Baskett
10% owner
Sep 16, 2024Conversion+2,091,383––3,114,486
Forest Baskett
10% owner
Sep 16, 2024Conversion+1,023,103––1,023,103
Forest Baskett
10% owner
Sep 16, 2024Buy+500,000$16.00$8.00M3,614,486
Scott D. Sandell
10% owner
Sep 16, 2024Conversion+2,091,383––3,114,486
Scott D. Sandell
10% owner
Sep 16, 2024Buy+500,000$16.00$8.00M3,614,486
Scott D. Sandell
10% owner
Sep 16, 2024Conversion+1,023,103––1,023,103
Paul Edward Walker
10% owner
Sep 16, 2024Conversion+2,091,383––3,114,486
Paul Edward Walker
10% owner
Sep 16, 2024Buy+500,000$16.00$8.00M3,614,486
Paul Edward Walker
10% owner
Sep 16, 2024Conversion+1,023,103––1,023,103
P. Kent Hawryluk
President & CEO, Director
Sep 16, 2024Conversion+115,914––398,277
P. Kent Hawryluk
President & CEO, Director
Sep 16, 2024Conversion+283,846––481,397
Biomedical Innovation Master Investors (Cayman) II L.P. Wellington
10% owner
Sep 16, 2024Conversion+403,787––1,790,122
Biomedical Innovation Master Investors (Cayman) II L.P. Wellington
10% owner
Sep 16, 2024Conversion+1,386,335––1,386,335
Rick Yang
10% owner
Sep 16, 2024Conversion+2,091,383––3,114,486
Rick Yang
10% owner
Sep 16, 2024Buy+500,000$16.00$8.00M3,614,486
Rick Yang
10% owner
Sep 16, 2024Conversion+1,023,103––1,023,103
Advisors Llc Orbimed
Director, 10% owner
Sep 16, 2024Buy+250,000$16.00$4.00M653,787
Advisors Llc Orbimed
Director, 10% owner
Sep 16, 2024Conversion+403,787––403,787
Advisors Llc Orbimed
Director, 10% owner
Sep 16, 2024Buy+500,000$16.00$8.00M3,158,428
Advisors Llc Orbimed
Director, 10% owner
Sep 16, 2024Conversion+2,658,428––2,658,428
Anthony A. Florence Jr.
10% owner
Sep 16, 2024Conversion+2,091,383––3,114,486

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
20.82%
4M shares short
Days to cover
7.9
At 1M shares a day
Change since last report
-3.1%
From 4M shares
Short volume, 20 days
46.5%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of MBX Biosciences's stock actually held short. Settlement fails (shares not delivered on time) peaked at 3,456 shares on Aug 27, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Steven L. Hoerter
Director
Nov 10, 20264,893$268.25KNov 10, 2026Restricted Stock Vesting
Salomon Azoulay
Officer
Nov 4, 2026373$20.13KNov 4, 2026Restricted Stock Vesting
P. Kent Hawryluk
Former Officer
Aug 17, 20263,745$255.74KAug 17, 2026Restricted Stock Vesting
Salomon Azoulay
Officer
Aug 4, 2026370$24.34KAug 4, 2026Restricted Stock Vesting
P. Kent Hawryluk
Officer, Director
Aug 4, 2026936$61.56KAug 4, 2026Restricted Stock Vesting
Richard Bartram
Former Officer
Jun 10, 20269,167$280.01KJun 10, 2026Stock Option Exercise
Richard Bartram
Former Officer
Jun 9, 202610,833$321.27KJun 9, 2026Stock Option Exercise
Richard Bartram
Former Officer
May 13, 202615,000$554.30KMay 13, 2026Option Granted - 08/15/2023
Richard Bartram
Former Officer
May 11, 202622,500$991.90KMay 11, 2026Option Granted - 04/20/2022
Salomon Azoulay
Officer
May 8, 202670,003$2.69MMay 8, 2026Option Granted - 09/12/2024
Richard Bartram
Former Officer
May 8, 202610,000$379.56KMay 8, 2026Option Granted - 04/20/2022
Richard Bartram
Former Officer
May 7, 202610,000$322.05KMay 7, 2026Option Granted 04/20/2022
Salomon Azoulay
Officer
May 6, 2026231$6.82KMay 6, 2026Restricted Stock Vesting
P. Kent Hawryluk
Officer, Director
May 6, 2026607$17.93KMay 6, 2026Restricted Stock Vesting
Richard Bartram
Former Officer
May 1, 20265,000$159.00KMay 1, 2026Options Granted - 04/20/2022

See a number that looks wrong?